Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021
Go back to Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021| IRONWOOD PHARMA-A (NASDAQ: IRWD) | Delayed: 3.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.82 | 52 Week High | $16.89 | |||
| Open | $3.82 | 52 Week Low | $7.35 | |||
| Day High | $3.82 | P/E | N/A | |||
| Day Low | $3.82 | EPS | $-2.35 | |||
| Volume | 21,345 | |||||
